TELA Bio
TELA
49 hedge funds and large institutions have $200M invested in TELA Bio in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
71% more capital invested
Capital invested by funds: $117M → $200M (+$83.2M)
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
9% more funds holding
Funds holding: 45 → 49 (+4)
3.36% more ownership
Funds ownership: 87.61% → 90.97% (+3.4%)
Top Buyers
Top Sellers
TELA Hedge Fund Activity: Q4 2022 in Review
49 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in TELA Bio (TELA) for Q4 2022, worth a combined $200M — up 71% from $117M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TELA positions and 3 closed out — a net gain of 4 holders — while 20 added to existing stakes and 12 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.54M. The largest seller was Granite Point Capital Management, cutting an estimated $1M.
- 49 institutional investors held TELA Bio (TELA) as of Q4 2022, up from 45 in Q3 2022.
- Funds reported $200M of TELA Bio stock for Q4 2022, up 71% quarter-over-quarter.
- 7 funds opened new TELA Bio positions in Q4 2022 and 3 closed out, a net change of +4 holders.
- The largest TELA Bio buyer in Q4 2022 was Vanguard Group, an estimated $2.54M added.
- The largest TELA Bio seller in Q4 2022 was Granite Point Capital Management, an estimated $1M sold.
Based on aggregated 13F filings for Q4 2022.